{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:15Z","timestamp":1790286915462,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T00:00:00Z","timestamp":1357776000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:p>Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (<jats:styled-content style=\"fixed-case\">sALCL<\/jats:styled-content>), which is a subtype of non\u2010<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>odgkin lymphoma, are relatively uncommon lymphoproliferative types of cancer. These malignancies are highly curable with initial treatment. Nonetheless, some patients are refractory to or relapse after first\u2010 and second\u2010line therapies, and outcomes for these patients are less promising. Brentuximab vedotin is a <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>30\u2010directed antibody\u2010cytotoxic drug conjugate that has demonstrated efficacy in response rates (objective response rates and complete response) when given to patients with refractory or relapsed HL and <jats:styled-content style=\"fixed-case\">sALCL<\/jats:styled-content>. Although not compared directly in clinical trials, the response rates with brentuximab vedotin are higher than those of several current treatments for refractory or relapsed HL and <jats:styled-content style=\"fixed-case\">sALCL<\/jats:styled-content>. Adverse effects associated with brentuximab vedotin are considered manageable. Nonetheless, several serious adverse effects (e.g., neutropenia, peripheral sensory neuropathy, tumor lysis syndrome, <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>tevens\u2010<jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>ohnson syndrome, and progressive multifocal leukoencephalopathy, resulting in death) have been reported with its use. Despite a lack of survival and patient reported outcome data, the United States <jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>ood and <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>rug <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>dministration (<jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>) granted accelerated approval to brentuximab vedotin for the treatment of HL after failure of autologous stem cell transplantation or at least two combination chemotherapy regimens, and for <jats:styled-content style=\"fixed-case\">sALCL<\/jats:styled-content> after failure of at least one combination chemotherapy regimen. With this approval, brentuximab vedotin is the first <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>\u2010approved agent for the treatment of HL in over three decades and the first agent specifically indicated to treat <jats:styled-content style=\"fixed-case\">sALCL<\/jats:styled-content>. Results of ongoing prospective trials should determine if brentuximab vedotin has a survival benefit when compared directly with standard treatment and if brentuximab vedotin is safe and efficacious when given earlier in the disease process, or when used with other chemotherapy for the treatment of HL and <jats:styled-content style=\"fixed-case\">sALCL<\/jats:styled-content> or other CD30\u2010positive malignancies.<\/jats:p>","DOI":"10.1002\/phar.1170","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T08:47:27Z","timestamp":1357807647000},"page":"93-104","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Brentuximab Vedotin: A <scp>CD<\/scp>30\u2010Directed Antibody\u2010Cytotoxic Drug Conjugate"],"prefix":"10.1002","volume":"33","author":[{"given":"Ashley M.","family":"Newland","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals Richmond Virginia"},{"name":"Virginia Commonwealth University School of Pharmacy Richmond Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny X.","family":"Li","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey E.","family":"Wasco","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals Richmond Virginia"},{"name":"Virginia Commonwealth University School of Pharmacy Richmond Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May T.","family":"Aziz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals Richmond Virginia"},{"name":"Virginia Commonwealth University School of Pharmacy Richmond Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise K.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals Richmond Virginia"},{"name":"Virginia Commonwealth University School of Pharmacy Richmond Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"key":"e_1_2_16_2_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology hodgkin lymphoma (version 1.2012). Available fromhttp:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf. Accessed February 4 2012."},{"key":"e_1_2_16_3_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology non\u2010Hodgkin's lymphomas (version 1.2012). Available fromhttp:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf. Accessed February 4 2012."},{"key":"e_1_2_16_4_1","volume-title":"Surveillance Epidemiology and End Results (SEER) cancer statistics review, 1975\u20132008","author":"Howlader N"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4101"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_16_7_1","unstructured":"National Cancer Institute. National Cancer Institute adult hodgkin lymphoma treatment (PDQ). Updated 23 Sept 2011. Available fromhttp:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/adulthodgkins\/HealthProfessional. Accessed February 15 2012."},{"issue":"4","key":"e_1_2_16_8_1","first-page":"iv120","article-title":"Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract]","volume":"19","author":"Horning S","year":"2008","journal-title":"Ann Oncol"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi119"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.2.179"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07727.x"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.584"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059010"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.017"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2007.01397.x"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11511"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23237"},{"key":"e_1_2_16_18_1","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8007","article-title":"Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed\/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT)","volume":"28","author":"Sureda A","year":"2010","journal-title":"J Clin Onc"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06164.x"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.02.005"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_16_23_1","volume-title":"Seattle Genetics, Inc. Adcetris (brentuximab vedotin)","year":"2012"},{"key":"e_1_2_16_24_1","unstructured":"U.S. Food and Drug Administration. News & events:FDA approves Adcetris to treat two types of lymphoma. 19 Aug 2011. Available fromhttp:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm268781.htm. Accessed February 4 2012."},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/299065a0"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32834bb8a7"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0488"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1417"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1425"},{"key":"e_1_2_16_31_1","article-title":"Long\u2010term survival analysis of an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"120","author":"Chen RW","year":"2012","journal-title":"Blood"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_16_33_1","article-title":"Long\u2010term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"120","author":"Pro B","year":"2012","journal-title":"Blood"},{"key":"e_1_2_16_34_1","unstructured":"ClinicalTrials.gov.A randomized double\u2010blind placebo\u2010controlled phase 3 study of SGN\u201035 and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT01100502. Accessed February 26 2012."},{"key":"e_1_2_16_35_1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.V118.21.955.955","article-title":"Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma","volume":"118","author":"Younes A","year":"2011","journal-title":"Blood"},{"key":"e_1_2_16_36_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.798.798","article-title":"Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma","volume":"120","author":"Ansell SM","year":"2012","journal-title":"Blood"},{"key":"e_1_2_16_37_1","unstructured":"Takeda Pharmaceutical Co. Seattle Genetics and Millennium report data from phase I trial of ADCETRIS\u2122(brentuximab vedotin) in front\u2010line Hodgkin lymphoma at American Society of Hematology annual meeting. Available fromhttp:\/\/www.takeda.com\/press\/article_43996.html. Accessed January 13 2012."},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-418673"},{"key":"e_1_2_16_39_1","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V118.21.3091.3091","article-title":"Allogeneic transplant following brentuximab vedotin treatment in patients with relapsed or refractory CD30\u00a0+\u00a0 lymphomas","volume":"118","author":"Illidge T","year":"2011","journal-title":"Blood"},{"key":"e_1_2_16_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397893"},{"key":"e_1_2_16_41_1","unstructured":"ClinicalTrials.gov. Available fromhttp:\/\/clinicaltrials\/gov\/ct2\/results?term=brentuximab. Accessed February 26 2012."},{"key":"e_1_2_16_42_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2454.2454","article-title":"Epigenetic modulation of CD30 gene expression in alemtuzumab resistant T cell malignancy: rational and efficacy of brentuximab vedotin","volume":"120","author":"Hasanali Z","year":"2012","journal-title":"Blood"},{"key":"e_1_2_16_43_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2746.2746","article-title":"A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30\u2010positive non\u2010Hodgkin lymphomas: interim results","volume":"120","author":"Jacobsen ED","year":"2012","journal-title":"Blood"},{"key":"e_1_2_16_44_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2857.2857","article-title":"Anti CD\u201030 antibody\u2010drug conjugate brentuximab vedotin (Adcetris) may be a promising treatment option for systemic mastocytosis (SM)","volume":"120","author":"Mehta A","year":"2012","journal-title":"Blood"},{"key":"e_1_2_16_45_1","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: new boxed warning and contraindication for Adcetris (brentuximab vedotin). Available fromhttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm287668.htm. Accessed January 13 2012."},{"key":"e_1_2_16_46_1","unstructured":"ClinicalTrials.gov.Clinical Pharmacology Study of Brentuximab Vedotin (SGN\u201035). Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT01026415. Accessed March 8 2012."},{"key":"e_1_2_16_47_1","unstructured":"Forero\u2010TorresA BerrymanRB AdvaniRH.Prolonged treatment with brentuximab vedotin (SGN\u201035) in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL) [abstract]. 53rd American Society of Hematology annual meeting and exposition. 2011. Available fromhttp:\/\/ash.confex.com\/ash\/2011\/webprogram\/Paper42148.html. Accessed February 18 2012."},{"key":"e_1_2_16_48_1","unstructured":"MerrillJ.Seattle Genetics will test oncology pricing acceptance with Adcetris. FDC Reports The Pink Sheet. August 29 2011."},{"key":"e_1_2_16_49_1","unstructured":"SeaGen Secure.SeaGen Secure Patient Assistance Program. Available fromhttp:\/\/www.seagensecure.com\/Accessed February 13 2012."},{"key":"e_1_2_16_50_1","unstructured":"NeedyMeds. SeaGen Secure Patient Assistance Program. Available fromhttp:\/\/www.needymeds.org\/generic_list.taf?_function=name&name=brentuximab%20vedotin. Accessed February 13 2012."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1170","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:24:28Z","timestamp":1761060268000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1002\/phar.1170"],"URL":"https:\/\/doi.org\/10.1002\/phar.1170","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"2013-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}